Revelation Biosciences, Inc. Warrant (REVBW)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Revelation Biosciences, Inc. Warrant Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BO Brian Oliveira Clear Street Group Inc. | 247,334 | $2,844.34 | $2,473.34 | -$371 | -13.04% |
Revelation Biosciences, Inc. Warrant (REVBW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Revelation Biosciences, Inc. Warrant ever had a stock split?
Revelation Biosciences, Inc. Warrant Profile
| Biotechnology Industry | Healthcare Sector | James Rolke CEO | NASDAQ (CM) Exchange | 76135L119 CUSIP |
| US Country | 8 Employees | - Last Dividend | - Last Split | 17 Nov 2020 IPO Date |
Overview
Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical enterprise committed to innovating within the realm of immune system therapeutics and diagnostics. Founded in the year 2020 and stationed in San Diego, California, the company takes pride in its robust pipeline designed to combat a variety of health concerns by harnessing the power of the immune system. By focusing on both therapeutic product candidates and diagnostic solutions, Revelation Biosciences aims to make significant advancements in how diseases and infections are prevented and treated, with a strong emphasis on healthcare-associated infections, viral infections, chronic organ diseases, and food allergies.
Products and Services
- REVTx-100
- REVTx-200
- REVTx-300
- REVTx-99b
- REVTx-99a
- REVDx-501
A pioneering therapeutic candidate with the potential to prevent and treat healthcare-associated bacterial infections. This innovation targets complications arising from surgery, severe burns, urinary tract infections, sepsis, and situations involving antibiotic resistance, showcasing the company’s commitment to addressing critical medical needs.
Slated as a potential intranasal therapy, REVTx-200 embodies Revelation Biosciences' approach to utilizing novel delivery systems to combat diseases at their entry points, providing a unique angle in therapeutic applications.
This potential therapy is at the forefront of tackling chronic organ diseases, including chronic kidney disease. By focusing on long-term health conditions, REVTx-300 represents a strategic diversification within Revelation Biosciences' portfolio, aiming to improve quality of life for individuals living with chronic ailments.
An innovative treatment under development for food allergies, REVTx-99b showcases Revelation Biosciences’ dedication to addressing prevalent health issues through novel therapeutic options, highlighting the company's broader commitment to enhancing patient outcomes across different medical fields.
As an anti-viral nasal drop solution, REVTx-99a is being developed for the potential prevention or treatment of respiratory viral infections. This product underscores the company’s agility in responding to contemporary health challenges, including but not limited to SARS-CoV-2, by crafting targeted and accessible solutions.
Envisioned as a rapid point of care in vitro diagnostic test, REVDx-501 aims to detect various respiratory viral infections, including influenza A, influenza B, parainfluenza, respiratory syncytial virus, and SARS-CoV-2. This diagnostic tool reflects Revelation Biosciences’ holistic approach to healthcare, acknowledging the critical role of swift and accurate diagnosis in the management of infections.
